- Home
- BE vs CGON Comparison
BE vs CGON Comparison
Compare BE & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BE
- CGON
- Stock Information
- Founded
- BE 2001
- CGON 2010
- Country
- BE United States
- CGON United States
- Employees
- BE N/A
- CGON N/A
- Industry
- BE Industrial Machinery/Components
- CGON
- Sector
- BE Energy
- CGON
- Exchange
- BE Nasdaq
- CGON NYSE
- Market Cap
- BE 2.3B
- CGON 2.4B
- IPO Year
- BE 2018
- CGON 2024
- Fundamental
- Price
- BE $24.12
- CGON $28.67
- Analyst Decision
- BE Buy
- CGON Strong Buy
- Analyst Count
- BE 19
- CGON 8
- Target Price
- BE $23.00
- CGON $63.88
- AVG Volume (30 Days)
- BE 7.7M
- CGON 932.1K
- Earning Date
- BE 02-13-2025
- CGON 02-02-2025
- Dividend Yield
- BE N/A
- CGON N/A
- EPS Growth
- BE N/A
- CGON N/A
- EPS
- BE N/A
- CGON N/A
- Revenue
- BE $1,258,379,000.00
- CGON $684,000.00
- Revenue This Year
- BE $9.34
- CGON $162.50
- Revenue Next Year
- BE $19.20
- CGON $17.62
- P/E Ratio
- BE N/A
- CGON N/A
- Revenue Growth
- BE N/A
- CGON 258.12
- 52 Week Low
- BE $8.41
- CGON $25.77
- 52 Week High
- BE $28.70
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- BE 55.30
- CGON 34.14
- Support Level
- BE $21.91
- CGON $27.00
- Resistance Level
- BE $27.06
- CGON $30.00
- Average True Range (ATR)
- BE 2.03
- CGON 2.03
- MACD
- BE -0.79
- CGON -0.42
- Stochastic Oscillator
- BE 33.61
- CGON 17.16
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and South Korea.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.